Navigation Links
Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board

To Advise in the Development of Periodontal Compound, 1-TDC

SAN DIEGO, Oct. 9 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the appointment of Dr. Thomas Van Dyke to its Medical Advisory Board. Dr. Van Dyke will provide guidance to Imagenetix on their experimental compound, 1-TDC, for the treatment and prevention of periodontal disease. Dr. Van Dyke is Professor, Department of Periodontology and Oral Biology, Boston University Goldman School of Dental Medicine.

Dr. Van Dyke has extensive experience as a consultant to medical advisory boards having participated on boards spanning the spectrum from start-up to major pharmaceutical companies in the industry. In addition, he has participated as an investigator in numerous clinical trails of products seeking FDA approval.

Dr. Van Dyke received his D.D.S. (1973) from Case Western Reserve University; M.S. (1979) from SUNY at Buffalo in Oral Sciences and his Ph.D. (1982) from SUNY at Buffalo in Oral Biology. He is a Diplomate of the American Board of Periodontology (1989), and he received the IADR Award for Basic Research in Periodontology in 2001 and the Norton Ross Award for Excellence in Clinical Research in 2002. He serves on the editorial boards of Infection and Immunity (1989-present); Journal of Periodontology (1988-present), Journal of Periodontal Research (1987-present); Journal of Clinical Periodontology (1991- 1995), Journal of Public Health Dentistry (1991-1995), Current Opinions in Periodontology (1993). He served as President of the Periodontal Diseases Research Group of the IADR from 1991-1992. Dr. Van Dyke has authored/co- authored 200+ original articles, and numerous abstracts and book chapters. He is a member of the American/International Association of Dental Research, American Academy of Periodontology, American Dental Association, and a Diplomate of the American Board of Periodontology. His research interests are the structural and functional relationship of abnormalities of the inflammatory process with focus on regulation of phagocytic cells, in the etiology and pathogenesis of periodontal diseases. He is best known for his work on the pathways of resolution of inflammation and pathogenesis of periodontal diseases, neutrophil biology, and clinical research.

"We are very excited to add an individual of Dr. Van Dyke's caliber and experience to our Medical Advisory Board", said Mr. William Spencer, President of Imagenetix. "We believe his joining our Medical Advisory Board validates the success of our periodontal studies at Boston University. We also believe that he will be instrumental in helping us through the FDA process for our periodontal compound 1-TDC which we feel could be a major breakthrough in prevention of periodontal disease."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit,

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.

SOURCE Imagenetix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. OpGen adds Thomas Pyle and James Ogle to board of directors
2. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
3. Wicab to present BrainPort at Boston conference
4. Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot
5. Boston entrepreneur to enliven Milwaukee angel group
6. Fermentation Cell Culture: University Style
7. Fueling our economy with the University of Wisconsin
8. CIO Leadership Series: Ed Meachen, University of Wisconsin System
9. University, business leaders convene in Wausau
10. University of South Florida expands GE Healthcare relationship
11. State and university form network for entrepreneurial outreach
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/25/2015)... PUNE, India , November 26, 2015 /PRNewswire/ ... The Global Biobanking Market 2016 - 2020 ... biobanks by maintaining integrity and quality in long-term ... and enabling long-term cost-effectiveness. Automation minimizes manual errors ... improves the technical efficiency. Further, it plays a ...
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:10/29/2015)... Minn. , Oct. 29, 2015   MedNet ... supports the entire spectrum of clinical research, is pleased ... Minnesota High Tech Association (MHTA) as one of only ... in the "Software – Small and Growing" category. The Tekne ... individuals who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):